KLRC2 and acute myeloid leukemia: The engager was demonstrated to direct NKG2C+ iPSC NK cells to target CD33+ AML cells and induce degranulation, IFN-γ production and cytotoxicity against the CD33+ cells and primary AML blasts (155).